To further provide a rationale for using HIF-1α inhibitors as an adjunctive medical therapy for small AAAs, we tested whether pharmacological HIF-1α inhibitors could attenuate AngII-induced AAA in vivo. Here, HIF1A is linked to triple-A syndrome.